🕒 Created · Updated

The Food and Drug Administration approved Eli Lilly's Mounjaro to reduce heart attack and stroke risks for adults with Type 2 diabetes.

The Food and Drug Administration approved Eli Lilly's Mounjaro to lower the risk of heart attack and stroke in high-risk adults with Type 2 disease. The drug, which already manages blood sugar, targets the GIP and GLP-1 hormone receptors. A large study submitted by Eli Lilly to the FDA showed that patients taking Mounjaro had an 8% lower rate of cardiovascular death, heart attack, or stroke compared to those taking the older diabetes drug Trulicity. Dr. Rachel Batterham, senior vice president of medical innovation and external engagement for cardiometabolic health at Eli Lilly, noted that cardiovascular disease is the primary cause of death for patients with Type 2 diabetes. While Mounjaro is already a popular GLP-1 medication, the new approval provides a's additional option for patients seeking to lower heart-related health risks. The drug is also prescribed for weight loss under the brand name Zepbound. Eli Lilly is currently conducting further studies to determine if the heart benefits of Zepbound apply to individuals without diabetes.

Sources